Medulloblastoma - Pipeline Review, H1 2016

SKU ID :GMD-10193477 | Published Date: 08-Jun-2016 | No. of pages: 96
Table of Contents Table of Contents 2 List of Tables 6 List of Figures 7 Introduction 8 Global Markets Direct Report Coverage 8 Medulloblastoma Overview 9 Therapeutics Development 10 Pipeline Products for Medulloblastoma - Overview 10 Pipeline Products for Medulloblastoma - Comparative Analysis 11 Medulloblastoma - Therapeutics under Development by Companies 12 Medulloblastoma - Therapeutics under Investigation by Universities/Institutes 13 Medulloblastoma - Pipeline Products Glance 14 Clinical Stage Products 14 Early Stage Products 15 Unknown Stage Products 16 Medulloblastoma - Products under Development by Companies 17 Medulloblastoma - Products under Investigation by Universities/Institutes 18 Medulloblastoma - Companies Involved in Therapeutics Development 19 Bayer AG 19 DelMar Pharmaceuticals, Inc. 20 Ignyta, Inc. 21 Lipocure Ltd. 22 MacroGenics, Inc. 23 Medicenna Therapeutics, Inc. 24 MEI Pharma, Inc. 25 Novartis AG 26 Novogen Limited 27 Progenics Pharmaceuticals, Inc. 28 Stemline Therapeutics, Inc. 29 Takeda Pharmaceutical Company Limited 30 Medulloblastoma - Therapeutics Assessment 31 Assessment by Monotherapy Products 31 Assessment by Combination Products 32 Assessment by Target 33 Assessment by Mechanism of Action 35 Assessment by Route of Administration 37 Assessment by Molecule Type 39 Drug Profiles 41 (topotecan hydrochloride + vincristine sulfate) - Drug Profile 41 Product Description 41 Mechanism of Action 41 R&D Progress 41 Cellular Immunotherapy to Target MAGE-A1, MAGE-A3 and NY-ESO-1 for Oncology - Drug Profile 42 Product Description 42 Mechanism of Action 42 R&D Progress 42 dianhydrogalactitol - Drug Profile 43 Product Description 43 Mechanism of Action 43 R&D Progress 43 Edotreotide Labeled Yttrium 90 - Drug Profile 46 Product Description 46 Mechanism of Action 46 R&D Progress 46 irinotecan hydrochloride + TBio-02 - Drug Profile 48 Product Description 48 Mechanism of Action 48 R&D Progress 48 LEQ-506 - Drug Profile 50 Product Description 50 Mechanism of Action 50 R&D Progress 50 MDNA-55 - Drug Profile 51 Product Description 51 Mechanism of Action 51 R&D Progress 51 Monoclonal Antibodies to Target IL13Ralpha2 and CD3 for Melanoma and Medulloblastoma - Drug Profile 52 Product Description 52 Mechanism of Action 52 R&D Progress 52 Monoclonal Antibodies to Target ROR1 and CD3 for Oncology - Drug Profile 53 Product Description 53 Mechanism of Action 53 R&D Progress 53 nifurtimox - Drug Profile 54 Product Description 54 Mechanism of Action 54 R&D Progress 54 nifurtimox SR - Drug Profile 55 Product Description 55 Mechanism of Action 55 R&D Progress 55 p28 - Drug Profile 56 Product Description 56 Mechanism of Action 56 R&D Progress 56 pracinostat - Drug Profile 58 Product Description 58 Mechanism of Action 58 R&D Progress 58 siomycin A - Drug Profile 60 Product Description 60 Mechanism of Action 60 R&D Progress 60 SL-301 - Drug Profile 61 Product Description 61 Mechanism of Action 61 R&D Progress 61 Small Molecules to Inhibit Hedgehog Signaling for Medulloblastoma - Drug Profile 62 Product Description 62 Mechanism of Action 62 R&D Progress 62 taladegib - Drug Profile 63 Product Description 63 Mechanism of Action 63 R&D Progress 63 THR-317 - Drug Profile 65 Product Description 65 Mechanism of Action 65 R&D Progress 65 Trilexium - Drug Profile 68 Product Description 68 Mechanism of Action 68 R&D Progress 68 VMY-1103 - Drug Profile 70 Product Description 70 Mechanism of Action 70 R&D Progress 70 Medulloblastoma - Recent Pipeline Updates 71 Medulloblastoma - Dormant Projects 89 Medulloblastoma - Product Development Milestones 90 Featured News & Press Releases 90 Mar 15, 2016: FDA Grants Second Orphan Designation For VAL-083 90 Feb 19, 2016: Novogen Patent Covering Trilexium Has Been Proceeded To Grant 91 Nov 11, 2015: DelMar Pharmaceuticals Presents Data Supporting VAL-083 as a Promising Potential Treatment for Pediatric Brain Tumors 91 Sep 19, 2011: Researchers Discover Regulatory Protein As Potential Drug Target For Brain Tumors 93 Appendix 95 Methodology 95 Coverage 95 Secondary Research 95 Primary Research 95 Expert Panel Validation 95 Contact Us 95 Disclaimer 96
Bayer AG DelMar Pharmaceuticals, Inc. Ignyta, Inc. Lipocure Ltd. MacroGenics, Inc. Medicenna Therapeutics, Inc. MEI Pharma, Inc. Novartis AG Novogen Limited Progenics Pharmaceuticals, Inc. Stemline Therapeutics, Inc. Takeda Pharmaceutical Company Limited
  • PRICE
  • $2000
    $6000

Our Clients